艾瑞纳制药有限公司宣布,其治疗肺动脉高压病新药ralinepag已开始Ⅱ期临床评价试验的剂量调整阶段。Ⅱ期临床试验是22周的随机、双盲、安慰剂对照,评价此药对60名肺动脉高压患者的血流动力学、对运动能力的影响,安全性和耐受性。前9周为每名患者确定该药的耐受量,且此用量保持到试验结束。肺动脉 Irina Pharmaceutical Co., Ltd. announced that its treatment of pulmonary hypertension new drug ralinepag has begun phase Ⅱ clinical evaluation test dose adjustment phase. Phase II clinical trial was a 22-week randomized, double-blind, placebo-controlled trial to evaluate the hemodynamic, locomotor-related, safety and tolerability of this drug in 60 patients with pulmonary hypertension. The first nine weeks for each patient to determine the tolerance of the drug, and the amount remained until the end of the trial. Pulmonary artery